Improving the treatment of malaria

Nick’s PRF aims to improve the treatment of malaria and thereby contribute to malaria elimination. Building on extensive studies of antimalarial pharmacokinetics, pharmacokinetic-pharmacodynamic relationships will be characterised for efficacy and toxicity. This involves development of field-adapted assay methodologies, optimal design population pharmacokinetic studies, and clinical studies in severe and uncomplicated falciparum and vivax malaria. Dose modification in important sub-groups such as young children, pregnant women, and HIV and tuberculosis co-infected patients should improve therapeutic responses and reduce selective pressures to the emergence of resistance.